Literature DB >> 34836782

The amoeboid state as part of the epithelial-to-mesenchymal transition programme.

Vittoria Graziani1, Irene Rodriguez-Hernandez1, Oscar Maiques1, Victoria Sanz-Moreno2.   

Abstract

Cell migration is essential for many biological processes, while abnormal cell migration is characteristic of cancer cells. Epithelial cells become motile by undergoing epithelial-to-mesenchymal transition (EMT), and mesenchymal cells increase migration speed by adopting amoeboid features. This review highlights how amoeboid behaviour is not merely a migration mode but rather a cellular state - within the EMT spectra - by which cancer cells survive, invade and colonise challenging microenvironments. Molecular biomarkers and physicochemical triggers associated with amoeboid behaviour are discussed, including an amoeboid associated tumour microenvironment. We reflect on how amoeboid characteristics support metastasis and how their liabilities could turn into therapeutic opportunities.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  actomyosin; amoeboid migration; cancer stem cells; epithelial-to-mesenchymal transition; immunosuppression; therapy resistance

Mesh:

Year:  2021        PMID: 34836782     DOI: 10.1016/j.tcb.2021.10.004

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  10 in total

Review 1.  Tumour invasion and dissemination.

Authors:  Ryan Lusby; Philip Dunne; Vijay K Tiwari
Journal:  Biochem Soc Trans       Date:  2022-06-30       Impact factor: 4.919

2.  RNA Binding Motif Protein 3 Promotes Cell Metastasis and Epithelial-Mesenchymal Transition Through STAT3 Signaling Pathway in Hepatocellular Carcinoma.

Authors:  Lu Zhang; Yi Zhang; Dongliang Shen; Ying Chen; Jianguo Feng; Xing Wang; Lunkun Ma; Yi Liao; Liling Tang
Journal:  J Hepatocell Carcinoma       Date:  2022-05-09

Review 3.  The emerging roles of exosomal long non-coding RNAs in bladder cancer.

Authors:  Qiang Liu
Journal:  J Cell Mol Med       Date:  2022-01-03       Impact factor: 5.310

4.  BAP31 Regulates Wnt Signaling to Modulate Cell Migration in Lung Cancer.

Authors:  Tianye Li; Zhenzhen Hao; Zihan Tang; Chunting Li; Linglin Cheng; Tao Wang; Xiaojin Zhu; Yunhao He; Yongye Huang; Bing Wang
Journal:  Front Oncol       Date:  2022-03-10       Impact factor: 6.244

5.  Regulation of Let-7a-5p and miR-199a-5p Expression by Akt1 Modulates Prostate Cancer Epithelial-to-Mesenchymal Transition via the Transforming Growth Factor-β Pathway.

Authors:  Abdulrahman Alwhaibi; Varun Parvathagiri; Arti Verma; Sandeep Artham; Mir S Adil; Payaningal R Somanath
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

Review 6.  Regulation of epithelial-mesenchymal transition by protein lysine acetylation.

Authors:  Fanyun Kong; Lihong Ma; Xing Wang; Hongjuan You; Kuiyang Zheng; Renxian Tang
Journal:  Cell Commun Signal       Date:  2022-04-28       Impact factor: 7.525

7.  RhoA-ROCK competes with YAP to regulate amoeboid breast cancer cell migration in response to lymphatic-like flow.

Authors:  Amina Mohammadalipour; Miguel F Diaz; Megan Livingston; Adesuwa Ewere; Allen Zhou; Paulina D Horton; Loretta T Olamigoke; John M Lamar; John P Hagan; Hyun J Lee; Pamela L Wenzel
Journal:  FASEB Bioadv       Date:  2022-02-14

Review 8.  Intermediate filaments: Integration of cell mechanical properties during migration.

Authors:  Elvira Infante; Sandrine Etienne-Manneville
Journal:  Front Cell Dev Biol       Date:  2022-08-05

Review 9.  Microfluidic Lab-on-a-Chip for Studies of Cell Migration under Spatial Confinement.

Authors:  Federico Sala; Carlotta Ficorella; Roberto Osellame; Josef A Käs; Rebeca Martínez Vázquez
Journal:  Biosensors (Basel)       Date:  2022-08-05

Review 10.  Chemokine/GPCR Signaling-Mediated EMT in Cancer Metastasis.

Authors:  Xutengyue Tian; Jiayi Wang; Lanxin Jiang; Yuchen Jiang; Juan Xu; Xiaodong Feng
Journal:  J Oncol       Date:  2022-10-11       Impact factor: 4.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.